Citations

Showing 10 of 108119 citations.

Cardiac Remodeling and Disease Progression in Patients With Repaired Coarctation of Aorta and Aortic Stenosis
Egbe, Alexander C. , Oh, Jae K. , Pellikka, Patricia A.

Mayo Clinic

Circulation: Cardiovascular Imaging | December 21, 2021 | Volume: 14 | Issue: 12 | Pages: 1091-1099

10.1161/circimaging.121.013383 | PMID 34932381 Get It

Background: Valvulo-arterial impedance (Zva) is used for assessment of left ventricular (LV) global pressure load in patients with aortic stenosis (AS) and impaired arterial compliance. Because patients with repaired coarctation of aorta (COA) have impaired arterial compliance, we hypothesized that COA patients with greater than or equal to moderate AS (AS-COA group) will have higher Zva, symptomatic progression, and cardiovascular events, as compared to non-COA patients with similar AS severity (AS group). Methods: Propensity matching (1:1) of 71 AS-COA and 71 AS patients based on age, sex, body mass index, and aortic valve mean gradient (cohort 1). Of 172 patients, 117 patients (AS-COA [n=62]; AS [n=55]) underwent aortic valve replacement, cohort 2. Cohort 1 was used to assess the relationship between preoperative Zva, cardiac remodeling, and symptomatic progression, while cohort 2 was used to assess the relationship between postoperative Zva, LV mass index regression (reduction in LV mass index after aortic valve replacement), and cardiovascular events. Results: The AS-COA group had higher Zva (4.2±0.6 versus 3.5±0.4 mm Hg/mL·m 2 , P <0.001), more advanced cardiac remodeling, and higher 5-year incidence of symptomatic progression (85% versus 51%, P <0.001). Preoperative Zva was independently associated with cardiac remodeling (r=0.66, P <0.001) and symptomatic progression (hazard ratio, 1.06 [1.02–1.10], per mm Hg/mL·m 2 increase in Zva). The AS-COA group had higher postoperative Zva (3.3±0.5 versus 2.4±0.4 mm Hg/mL·m 2 , P <0.001), less robust LV mass index regression at 1-year post–aortic valve replacement, and higher 5-year incidence of cardiovascular events. Postoperative Zva was independently associated with LV mass index regression (r=−0.46, P <0.001) and cardiovascular events (hazard ratio, 1.06 [1.02–1.10], per mm Hg/mL·m 2 increase in Zva). Conclusions: Adults with AS-COA had higher LV global pressure load, cardiac remodeling, symptomatic progression, and cardiovascular events as compared to non-COA patients with similar severity of AS. Zva can identify patients at risk for adverse outcomes, and perhaps should be used for risk stratification with regards to timing of aortic valve replacement.
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, Michael A. , Brown, Paul D. , Messersmith, Hans , Brastianos, Priscilla K. , Burri, Stuart H., Dunn, Ian F. , Gaspar, Laurie E., Gatson, Na Tosha , Gondi, Vinai , Lassman, Andrew B. , Maués, Julia , Mohile, Nimish, Redjal, Navid , Stevens, Glen , Bent, Martin J. van den , Wallace, H. James , Weinberg, Jeffrey S. , Zadeh, Gelareh , Schiff, David , van den Bent, Martin J , Gatson, Na Tosha N , Redjal, Navid , Messersmith, Hans , Cahill, Daniel P. , Jordan, Justin T. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | December 21, 2021 | Volume: 24 | Issue: 3 | Pages: 331-357

10.1093/neuonc/noab262 Get It

Abstract Purpose To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a systematic review of the literature. Results Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. Recommendations Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status &lt; 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines.
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, Michael A. , Brown, Paul D. , Messersmith, Hans , Brastianos, Priscilla K. , Burri, Stuart H., Dunn, Ian F. , Gaspar, Laurie E., Gatson, Na Tosha , Gondi, Vinai , Jordan, Justin T. , Lassman, Andrew B. , Maués, Julia , Mohile, Nimish, Redjal, Navid , Stevens, Glen , Bent, Martin J. van den , Wallace, H. James , Weinberg, Jeffrey S. , Zadeh, Gelareh , Schiff, David , Gatson, Na Tosha N , Jordan, Justin T , Lassman, Andrew B , Maues, Julia , Redjal, Navid , Stevens, Glen , Sulman, Erik P , van den Bent, Martin J , Wallace, H James , Messersmith, Hans , Cahill, Daniel P. , Sulman, Erik P.

Mayo Clinic

Journal of Clinical Oncology | December 21, 2021 | Volume: 40 | Issue: 5 | Pages: 492-516

10.1200/jco.21.02314 | PMID 34932393 Get It

PURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non–small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines .
Scoping review to evaluate existing measurement parameters and clinical outcomes of transtibial prosthetic alignment and socket fit
Won, Nae Yeon , Paul, Alexandra , Garibaldi, Matthew , Baumgartner, Rita E. , Kaufman, Kenton R., Reider, Lisa , Wrigley, Jordan , Morshed, Saam , Won, Nae Yeon , Paul, Alexandra , Garibaldi, Matthew , Baumgartner, Rita E. , Kaufman, Kenton R., Reider, Lisa , Wrigley, Jordan , Morshed, Saam

Mayo Clinic

Prosthetics & Orthotics International | December 21, 2021 | Volume: 46 | Issue: 2 | Pages: 95-107

10.1097/pxr.0000000000000061 | PMID 35412519 Get It

Introduction: Fit and alignment are observable objectives of the prosthesis rendering process for individuals with lower limb amputation. Nevertheless, there is a dearth of validated measures to directly assess the quality of this clinical procedure. Objectives: The objectives of this scoping review are to evaluate existing measurement parameters and clinical outcomes used in investigations of transtibial socket fit or prosthetic alignment and to identify gaps in the literature regarding tools for evaluation of prosthetic fitting. Study design: Scoping literature review. Methods: A comprehensive search was conducted in the following databases: MEDLINE (through PubMed), Embase (through Elsevier), Scopus (through Elsevier), and Engineering Village (through Elsevier), resulting in 6107 studies to be screened. Results: Sixty-three studies were included in the review. When measuring fit, studies most frequently reported on patient-reported comfort (n = 22) and socket size compared with the residual limb volume (n = 9). Alignment was most frequently measured by the prosthetists' judgment and/or use of an alignment jig (n = 34). The measurement parameters used to determine alignment or fit varied greatly among the included studies. Conclusion: This review demonstrated that most measures of socket fit rely on a patient's self-report and may vary with biopsychosocial factors unrelated to the socket fitting process. Meanwhile, alignment is determined mostly by the prosthetist's judgment, paired with objective measurements, such as alignment jigs and gait analysis. Efforts to standardize and validate measures of these parameters of prosthetic fitting are vital to improving clinical practice and reporting outcomes.
International Orthopaedic Volunteer Opportunities in Low and Middle-Income Countries
Miclau, Theodore , MacKechnie, Madeline C. , Born, Christopher T. , MacKechnie, Michael A. , Dyer, George S.M. , Yuan, Brandon J. , Dawson, John A. , Lee, Cassandra, Ishmael, Chad R. , Schreiber, Verena M. , Ulmer, Todd , Shearer, David , Johal, Herman , Sprague, Sheila , Whiting, Paul S. , Roberts, Heather J. , Coughlin, Richard, Gosselin, Rich, Rosenwasser, Melvin P. , Johnson, Anthony, Babu, Jacob , Dworkin, Myles , Makhni, Melvin C. , McClellan, Trigg, Nwachuku, Chinenye O., Miclau, Elizabeth, Dawson, John , Ulmer, Todd , Shearer, David W , Agarwal-Harding, Kiran J , Khormaee, Sariah , Sprague, Sheila , Whiting, Paul S , Roberts, Heather J , Dworkin, Myles , Makhni, Melvin C , Nwachuku, Chinenye O , Miclau, Elizabeth , Dyer, George , Yuan, Brandon , Tejwani, Nirmal C. , Gosselin, Richard Andre , Morshed, Saam

Mayo Clinic

Journal of Bone and Joint Surgery | December 21, 2021 | Volume: 104 | Issue: 10 | Pages: e44

10.2106/jbjs.21.00948 | PMID 34932526 Get It

Abstract: Globally, the burden of musculoskeletal conditions continues to rise, disproportionately affecting low and middle-income countries (LMICs). The ability to meet these orthopaedic surgical care demands remains a challenge. To help address these issues, many orthopaedic surgeons seek opportunities to provide humanitarian assistance to the populations in need. While many global orthopaedic initiatives are well-intentioned and can offer short-term benefits to the local communities, it is essential to emphasize training and the integration of local surgeon-leaders. The commitment to developing educational and investigative capacity, as well as fostering sustainable, mutually beneficial partnerships in low-resource settings, is critical. To this end, global health organizations, such as the Consortium of Orthopaedic Academic Traumatologists (COACT), work to promote and ensure the lasting sustainability of musculoskeletal trauma care worldwide. This article describes global orthopaedic efforts that can effectively address musculoskeletal care through an examination of 5 domains: clinical care, clinical research, surgical education, disaster response, and advocacy.
Anterior Cruciate Ligament Reconstruction Recovery and Rehabilitation
Glattke, Kaycee , Tummala, Sailesh V. , Chhabra, Anikar , Glattke, Kaycee E , Chhabra, Anikar , Tummala, Sailesh V

Mayo Clinic

Journal of Bone and Joint Surgery | December 21, 2021 | Volume: 104 | Issue: 8 | Pages: 739-754

10.2106/jbjs.21.00688 | PMID 34932514 Get It

Background: The success of anterior cruciate ligament (ACL) reconstruction is influenced by effective rehabilitation. Previously published, comprehensive systematic reviews evaluating rehabilitation after ACL reconstruction have studied Level-I and II evidence published through 2012. Interval studies continue to evaluate the efficacy of various rehabilitative modalities. Methods: A total of 824 articles from 2012 to 2020 were identified using multiple search engines. Fifty Level-I or II studies met inclusion criteria and were evaluated using the Consolidated Standards of Reporting Trials (CONSORT) criteria and National Institutes of Health (NIH) Study Quality Assessment Tools. Results: Accelerated rehabilitation can be effective for patients with semitendinosus-gracilis grafts. Blood flow restriction (BFR) training with high-intensity exercise is not effective for ACL reconstruction recovery. Postoperative bracing does not offer any advantages or improve limb asymmetry. Cryotherapy is an effective analgesic when used perioperatively. The early introduction of open kinetic chain exercises may improve ACL reconstruction outcomes, and high-intensity plyometric exercise is not effective. Estimated pre-injury capacity (EPIC) levels may be more accurate than the Limb Symmetry Index (LSI) when using functional test results to predict reinjury rates, and hip external rotation strength may be the most accurate predictor of the hop test performance. Nerve blocks can provide postoperative analgesia with minimal complication risk. Neuromuscular electrical stimulation is effective when used independently and in combination with rehabilitative exercises. Psychological readiness should be evaluated both objectively and subjectively before allowing patients to safely return to sport. Electromyography biofeedback may help to regain muscular function, and whole-body vibration therapy can improve postural control. Supervised rehabilitation is more effective than unsupervised rehabilitation. Conclusions: Various rehabilitative modalities following ACL reconstruction are effective in improving surgical outcomes and return-to-sport rates. Further evidence and improved study design are needed to further validate modalities including accelerated rehabilitation, BFR training, functional testing, and return-to-sport criteria. Level of Evidence: Therapeutic Level II . See Instructions for Authors for a complete description of levels of evidence.
Factors Affecting the Risk of Aseptic Patellar Complications in Primary TKA Performed with Cemented All-Polyethylene Patellar Resurfacing
Limberg, Afton K. , Tibbo, Meagan E. , Ollivier, Matthieu , Tammachote, Nattapol , Abdel, Matthew P. , Berry, Daniel J. , Abdel, Matthew P , Berry, Daniel J , Limberg, Afton K. , Tibbo, Meagan E. , Ollivier, Matthieu , Tammachote, Nattapol

Mayo Clinic

Journal of Bone and Joint Surgery | December 21, 2021 | Volume: 104 | Issue: 5 | Pages: 451-458

10.2106/jbjs.21.00356 | PMID 34932523 Get It

Background: Patellar complications are a consequential cause of failure of primary total knee arthroplasty (TKA). The purpose of this study was to evaluate the association of demographic and patient factors with the long-term risk of patellar complications as a function of time in a very large cohort of primary TKAs performed with patellar resurfacing. Methods: We identified 27,192 primary TKAs utilizing cemented all-polyethylene patellar components that were performed at a single institution from 1977 through 2015. We evaluated the risk of any aseptic patellar complication and any aseptic patellar reoperation or revision, subanalyzed risks of reoperation or revision for loosening, maltracking/instability, and wear, and evaluated the risk of clinical diagnosis of patellar fracture and clunk/crepitus. The mean age at TKA was 68 years (range, 18 to 99 years); 57% of the patients were female. The mean body mass index (BMI) was 32 kg/m 2 . The primary diagnosis was osteoarthritis in 83%, and 70% of the TKAs were posterior-stabilized. Median follow-up was 7 years (range, 2 to 40 years). Risk factors for each outcome were evaluated with Cox regression models. Results: Nine hundred and seventy-seven knees with all-polyethylene patellae developed patellar complications. Survivorship free from any aseptic patellar complication was 93.3% at 20 years. Twenty-year survivorship free from any aseptic patellar reoperation was 97.3% and free from any aseptic patellar revision was 97.4%. Fifteen-year survivorship for the same end points for procedures performed from 2000 to 2015 was 95.7%, 99.2% and 99.3% respectively, representing substantial improvements compared with implants placed before 2000. Univariate analysis demonstrated that male sex (hazard ratio [HR], 1.4), an age of <65 years (HR, 1.3), and a BMI of ≥30 kg/m 2 (HR, 1.2) were associated with increased risk of patellar complications (all p ≤0.01). Posterior-stabilized designs were associated with fewer patellar reoperations and revisions overall (HR, 0.4 and 0.4; p < 0.001) but higher risk of patellar clunk/crepitus (HR, 14.1; p < 0.001). Conclusions: The 20-year survivorship free from any aseptic patellar complication in this series of cemented all-polyethylene patellae was 93%. Important risk factors for any aseptic patellar complication were male sex, an age of <65 years, a BMI of ≥30 kg/m 2 , and a patella implanted before 2000. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish
Li, Jiarong , Zhu, Ping , Shih, Yu-Huan, Wang, Mingmin , Zhang, Yuji , Xu, Xiaolei , Bu, Haisong, Ding, Yonghe , Lin, Xueying , Wang, Mingmin , Bu, Haisong

Mayo Clinic

JCI Insight | December 21, 2021 | Volume: 6 | Issue: 24 | Pages: No page available

10.1172/jci.insight.154215 | PMID 34935644 Get It

Myosin heavy chain 7 (MYH7) is a major causative gene for hypertrophic cardiomyopathy, but the affected signaling pathways and therapeutics remain elusive. In this research, we identified ventricle myosin heavy chain like ( vmhcl ) as a zebrafish homolog of human MYH7 , and we generated vmhcl frameshift mutants. We noted vmhcl -based embryonic cardiac dysfunction (VEC) in the vmhcl homozygous mutants and vmhcl -based adult cardiomyopathy (VAC) phenotypes in the vmhcl heterozygous mutants. Using the VEC model, we assessed 7 known cardiomyopathy signaling pathways pharmacologically and 11 candidate genes genetically via CRISPR/Cas9 genome editing technology based on microhomology-mediated end joining (MMEJ). Both studies converged on therapeutic benefits of mTOR or mitogen-activated protein kinase (MAPK) inhibition of VEC. While mTOR inhibition rescued the enlarged nuclear size of cardiomyocytes, MAPK inhibition restored the prolonged cell shape in the VEC model. The therapeutic effects of mTOR and MAPK inhibition were later validated in the VAC model. Together, vmhcl/myh7 loss of function is sufficient to induce cardiomyopathy in zebrafish. The VEC and VAC models in zebrafish are amenable to both efficient genetic and chemical genetic tools, offering a rapid in vivo platform for discovering candidate signaling pathways of MYH7 cardiomyopathy.